carbidopa has been researched along with nystatin a1 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Aperia, A; Ballermann, BJ; Brenner, BM; Gullans, SR; Kone, BC; Seri, I | 1 |
1 review(s) available for carbidopa and nystatin a1
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for carbidopa and nystatin a1
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Locally formed dopamine inhibits Na+-K+-ATPase activity in rat renal cortical tubule cells.
Topics: Animals; Carbidopa; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Dopamine; Enzyme Inhibitors; In Vitro Techniques; Kidney Cortex; Kidney Tubules, Proximal; Kinetics; Levodopa; Male; Nystatin; Ouabain; Oxygen Consumption; Rats; Rats, Inbred Strains; Rubidium; Sodium-Potassium-Exchanging ATPase | 1988 |